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Summary 
The interaction between CD40 ligand and CD40 is critical for activation of T  and B  cells in 
vivo. We have recently demonstrated that this interaction rapidly induces a novel costimulatory 
activity distinct from B7 and independent  of CD28.  To study the molecular basis  of the co- 
stimulatory activity, we have produced a novel monoclonal antibody, TM-1, that binds an 85- 
kilodalton costimulatory molecule rapidly induced by CD40L. Expression cloning reveals that 
TM-1 binds CD44H. CD44H expressed on Chinese hamster ovary cells has potent costimula- 
tory activity for clonal expansion ofT cells isolated from both wild-type mice and those with a 
targeted mutation of CD28.  Thus, CD44H costimulates T  cell proliferation by a CD28-inde- 
pendent  mechanism. These results revealed that CD44H is a costimulatory molecule rapidly 
induced by CD40L. 
C 
ognate  interactions  between  T  cells  and  B  cells  are 
critical not only for B cell activation but also for T  cell 
responses.  The interaction between  CD40L  and  CD40  is 
one such example. It is now well established that this inter- 
action is essential for proliferation and differentiation of B 
cells,  particularly for the formation of germinal center and 
memory B cells (1-8). Recent data also illustrate an impor- 
tant  role for such  interaction  in  the  activation of T  cells. 
Two groups have recently reported that priming of CD4 T 
cells is defective in mice with a targeted mutation of either 
CD40 or CD40L (9,  10). While the mechanism for the de- 
fect is still unclear, an attractive hypothesis is that this inter- 
action  is important because of its induction  of costimula- 
tory activity on the APCs (11,  12).  This hypothesis would 
explain  the  parallel induction  of immunological tolerance 
when the TCtL is engaged in the absence of costimulation 
(13-17)  and  when  CD40L/CD40  interaction  is  blocked 
(18).  Furthermore, using mice with a targeted mutation of 
the  CD40L  gene,  we  have  recently  demonstrated  that 
CD40L  is  critical  for  optimal  induction  of costimulatory 
activity on APCs  (19).  This hypothesis has not been criti- 
cally tested largely because the  molecular basis  of the  co- 
stimulatory activity induced by CD4OL/CD40  interaction 
is not well understood. 
Yong Guo and Yan Wu contributed equally to this study. 
Several groups have presented evidence that CD40L can 
up-regulate  costimulatory molecules such  as B7-1  and/or 
B7-2  (1,  20,  21),  and  they  have  suggested  the  induced- 
expression of B7 family members as an explanation for the 
induction  of costimulatory activity on B  cells  by CD40L. 
However, a careful examination of the kinetics of the in- 
duction of the costimulatory activity and that of B7 family 
members suggests that  this is  unlikely  to be the  case. We 
showed that  CD40L induces  significant  costimulatory ac- 
tivity within 3 h; yet, B7-2 was not induced until 12 h, and 
B7-1  was not induced  in  the first 48  h  after B  cells  were 
stimulated by CD40L  (19).  In addition,  when activated T 
cells are incubated with B cells, CD40L is essential for opti- 
mal induction  of costimulatory activity but not for that of 
B7-2. Furthermore, the CD40L-induced costimulatory ac- 
tivity functions in the absence of CD28,  in contrast to B7 
family  members  that  induce  a  poor  clonal  expansion  of 
CD28(-/-)  CD4  T  cells.  Consistent  with  this  notion, 
Schultz et al. has recently reported that induction  of B7-1 
and B7-2 does not explain the CD40L-induced costimula- 
tory activity on  a  large  panel  of leukemic  cell lines  (22). 
Taken together, these studies demonstrate that CD40L rap- 
idly induces a novel costimulatory activity on APCs. 
To  identify  the  costimulatory  molecules  induced  by 
CD40L, we have generated an mAb, TM-1, that appears to 
bind a costimulatory molecule induced by CD40L for the 
following reasons (19).  First,  TM-1  almost completely in- 
hibits  the  costimulatory activity induced  by CD40L.  Sec- 
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the  induction  of TM-1  epitope  correlates with  that  of the 
costimulatory  activity.  Third,  TM-1  binds  a  molecule  of 
"~  kD,  which  is  distinct  from  B7,  HSA,  and  ICAM-1. 
Here  we report  that  TM-1  and  another  mAb  with  similar 
properties,  9C5,  bind  CD44H  and  that  CD44H  has  co- 
stimulatory  activity  for  clonal  expansion  of T  cells  by  a 
CD28-independent  mechanism. 
Materials and Methods 
Experimental Animals, Cell Lines, and mAbs.  CBA/CaJ  and 
C57BL/6j  mice  were  purchased  from  The Jackson  Laboratory 
(Bar  Harbor,  ME).  Mice  with  a  targeted  mutation  of CD28 
(CD28KO mice) (23) were kindly provided by Dr. T. Mak (Uni- 
versity  of Toronto,  Toronto,  Ontario,  Canada)  and  have  been 
backcrossed to C57BL/6j for six generations.  Spleens from these 
three  strains  of mice were  used  as  the  source  of T  and  B  cells, 
which were prepared as has been described (19). 
Both COS cells and Chinese hamster ovary (CHO) 1 cells were 
cultured in DMEM containing 5% of FCS.  The  transient  trans- 
fection of COS  cells and  stable  transfection  of CHO  cells have 
been described (24). 
Generation  of hamster  mAb  TM-I  has  been  described  (19). 
Another  mAb,  9C5,  was  produced  independently  by  a  similar 
procedure.  Fusion protein CTLA41g that  is comprised of extra- 
cellular domain of CTLA4 and Fc portion of murine Ig was pro- 
duced as described (25).  Anti-CD3 mAb 2Cll  (26)  was used to 
engage  the  TCR/CD3  complex.  HB224  (27),  a  hamster  IgG 
mAb to murine CD 1  lc, was used as control. 
Expression Cloning of Costimulatory Molecule Recognized by  TM-1. 
A  cDNA  library  was  prepared  from  a  B  leukemic  cell  line, 
RAW8.1,  that expresses high levels of TM-1  epitope by using a 
previously described method (28).  The eDNA library was used to 
transfect COS cells by DEAE-dextran method.  3 d after transfec- 
tion,  COS cells were harvested and  incubated with TM-1  mAb 
(5 tag/M) at 4~  for 1 h. Unbound mAb was removed by wash- 
ing, and the COS cells were incubated in petri dishes precoated 
with  goat  anti-hamster  IgG  antibodies  (Caltag,  San  Francisco, 
CA).  2  h  later,  the unbound  cells were washed extensively with 
PBS; the cells adhering to the plates were lysed, and the episomal 
DNA was prepared  as has  been  described  (28).  The  eDNA was 
used  to  transform  Escherichia coil MC1061/p3.  The  antibiotics- 
resistant colonies were amplified and pooled. Plasmids were pre- 
pared from pools of 50 colonies and used to transfect COS cells. 
Individual  colonies from the  positive pools were  amplified,  and 
their  plasmids  were  tested  for their  ability  to  transfer  TM-1 
epitope mto COS cells.  The positive clone was sequenced by an 
automatic DNA sequencer. 
T cell Proliferation.  Given  numbers  of CD4  T  cells  isolated 
from nmuse  spleens were stimulated with  1:40  dilution  of anti- 
CD3 hybridoma supernatants  (2Cll; Reference 26)  in the pres- 
ence of accessory cells. Syngeneic B  cells cultured with either xI*-2 
or CD40L-transfected xI*-2 for given periods were fixed with 0.1% 
paraformaldehyde  for 5 min and used as accessory cells.  In addi- 
tion,  FcP,-transfected  CHO  cells (CHOFcR),  or human  B7-1- 
transfected  CHOFctL,  or  CD44H-transfected  CHOFcP,.  were 
~  Abbreviations used in this paper: CHO, Chinese hamster ovary; CHOFcR, 
FcR-transfected  CHO cells; FITC-HA, FITC-labeled HA; HA, hyalu- 
ronic acid. 
treated with mitomycin C  (50 lag/ml) and used as accessory cells. 
T  cells cultured with accessory cells and anti-CD3 mAb for 42 h 
were pulsed with  1 laCi/well of 3H-TdR for an additional  6  h, 
and the incorporation of 3H-TdR was used as an indicator for T 
cell proliferation.  Anti-CD44 mAbs or hunmn  CD44Ig that  was 
known  to block  CD44H  binding  to  hyaluronic  acid  (HA)  (29) 
was added at the beginning of the culture to test the inhibition of 
T  cell prolfieration.  (Data presented are means of duplicates, with 
variations always <  15% of the means.) 
Cross-blocking  q[" mAb  Binding  to  CD4OL-activated  B  Cells. 
To test whether TM-I  and anti-CD44H mAb IMI.7  (30)  binds 
to the same molecules, we preincubated CD40L-activated B cells 
with unlabeled TM-1  or IM1.7  (100  ~g/ml)  for 30 rain on ice. 
Biotinylated TM-1  or lM1.7  was  then  added.  After another  30 
rain  of incubation,  unbound  mAbs were  washed  away  and  cell 
surface binding of the biotinylated mAb was detected by phyco- 
erythorin-streptavidin. 
In  other  experiments,  unlabeled  rat  mAb  IM1.7  was  used to 
block  the  binding of hamster/nAb  9C5.  The  method  is essen- 
tially identical except that FITC-labeled goat anti-hamster Ig (ad- 
sorbed by rat and mouse Ig) was used as the second-step reagent. 
Hyaluronate Binding Assay.  Unstimulated  T-depeleted  spleen 
cells or those that have been cocultured with either untransfected 
or  CD40L-transfected  ~-2  cells for  16  h  were  incubated  with 
FITC-labeled  HA  (FITC-HA)  (31)  for  45  nfin  on  ice  as  de- 
scribed (31).  The specificity of the staining was verified by block- 
ing with a  fivefotd excess of unconjugated  HA. CHO  cells that 
express endogenous hamster CD44 and bind HA well (29)  were 
used as positive control. 
Results 
Expression  Cloning  Reveals  Two  mAbs  that  Block  CD40L 
Induced Costimulatory Molecules Bind CD44H.  We  have  pre- 
pared  cDNA  from  a  B  leukemic  cell line,  RAW8.1,  that 
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Figure  1.  Expression cloning reveals that  TM-I binds C1)44H.  (a)  A 
single clone 3F isolated from the cDNA library prepared  from R.AW8.1 
cells transfer TM-1  epitope  into COS cells. Mock-transfected  or a single 
cDNA clone-transfected  COS  cells were incubated  with  mAb TM-I. 
This is followed by incubation  with the second-step  reagent, the FITC- 
labeled  goat anti-hamster  IgG,  and  analysis of the expression  of TM-I 
epitope  by  flow  cytometry.  ""',  second-step  reagent;  --,  nlock- 
transfected+TM-1;  -  -  -,  3F-transfectant+TM-1.  (b)  TM-1  and  anti- 
CD44H mAb IM1.7 cross-block each other's binding to CD40L-activated 
B cells. B cells from  CBA/CaJ mice were stimulated  by CD40L-trans- 
fected fibroblasts for 48 h. Viable cells isolated by centrifugation through  a 
Ficoll-hypaque medium were incubated with 100 lag/m] of either TM-I, 
IM1.7, or nomlal hamster Ig for 30 rain at 4~  Biotinylated mAbs, either 
TM-1  or IM1.7, were added and incubated  with the cells for another  3{) 
rain;  the binding of biotinylated mAbs was detected by phycoerythrin- 
labeled streptavidin.  "-", second-step  control:  @CI)44+ TM-1- 
biotin; - - -, medium+TM-l-biotin. 
956  CD44H Is a Costinmlatory Molecule Rapidly Induced by CD40L a  b 
L-- 
.IQ 
E 
Z 
i  ! 
U 
....  ted 
AA 
/Y,,/ 
C 
i  L 
il 
i  ~  ..-,.t~.,ezz4 
i  i  .... a,t~. so5 
i  i  --  ,,~7+scs 
12O0OO 
80000, 
40000" 
T:, 
~  ...... ,;3?0,  ...... ; 
l/dllutlonl 
d 
II 
/4  i 
......  i\?, .., 
ff "V  I 
CliO  ~ ;/  ' ! 
log Fluorescence 
Figure  2.  mAb 9C5 binds to a CD40L-induced costimulatory mole- 
cule and recognizes CD44H. (a) 9C5 recognized a CD40L-induced mol- 
ecule on B cells. B cells from C57BL6/j  mice were stimulated with either 
￿9 -2 or CD40L-transfected ~-2 for 16 h, and the expression of the 9C5 
epitopes was determined by flow cytometry. (b) 9C5 blocks the CD40L- 
induced costimulatory  activity.  Normal B  cells from  C57BL/6j  mice 
were cocultured  with CD40L-transfected  xlt-2 cells for 16 h, fixed with 
0.1% paraformaldehyde for 5 rain, and used as accessory cells for prolifer- 
ation ofCD4 T cells to anti-CD3 mAb 2C1 l  (added as 1:40 dilution of 
hybridomas supernatants). Given dilutions of supernatants from hybrido- 
mas (9C5, TM-1, or control hamster mAb HB224 that contain ~10 {Zg/ 
nil mAb) were added at the beginning of the culture.  (c) The binding of 
9C5 epitope was blocked by anti-CD44H mAb IM1.7. B cells cocultured 
with CD40L-transfected xP'-2  cells for 16 h were preincubated with either 
normal rat Ig or anti-CD44H mAb IM1.7 (100 gtg/ml) for 30 rain. The 
9C5 hybridoma supernatants were added, and its binding  was determined 
by using mouse/rat Ig adsorbed, FITC-labeled goat anti-hamster IgG. (d) 
mAb 9C5 binds CD44H-transfected,  but not untransfected CHO cells. 
Stable CD44H-transfected  or untransfected CHO  cells were  incubated 
with either 9C5 (top) or TM-1  (bottom) for 30 rain, the binding of mAbs 
was determined  by flow cytometry  using FITC-labeled,  goat anti-ham- 
ster IgG as the second-step reagent. 
Figure  3.  Rapid  inducflort of 
CD44  mRNA  by  ('I')4{)L.  B 
cells from  CBA/CaJ  mice  were 
stimulated  with  ('D41)L-tram- 
fected fibroblasts for 0, 2, 4, and 
8 h. The total cytoplasmic RNA 
were isolated, and the anmunt of 
the CD44 mRNA was detected 
by Northern blot using ~2P-lal~eled 
CD44H  cDNA  as  probe.  The 
amounts  of  RNA  loaded  are 
shown at the bottoCh. 
has  a  high  level  of TM-1  epitopes.  The  COS  cells  were 
transfected with the cDNA library, and the TM-1  epitope~ 
expressing COS cells were enriched by panning using TM-1. 
The small numbers of cells binding to the TM-1 mAb were 
lysed, and the episomal DNA were used to transform E, coli, 
800  colonies were  amplified, and cDNA  from pools of 50 
colonies were  used to  transfect COS  cells. Episomal DNA 
prepared  from one of such pools transferred the TM-1  re- 
activity  to  COS  cells.  A  single  clone  was  identified  that 
contains  the  gene  encoding  TM-1  (Fig.  I  a).  I)NA  ~e- 
quencing of the whole insert reveals that the cl)NA encodes 
CD44H  (data not shown).  Consistent with this, TM-I  and 
anti-CD44H mAb IM1,7  cross-block each  other's binding 
to  CD40L-induced B  cells (Fig.  1  b).  The extent of block- 
ing suggests  that the majority of the molecules recognized 
by TM-1 is CD44H. 
We have recently produced another mAb, 9C5,  that has 
similar  properties  to  TM-1.  As  shown  in  Fig.  2  a,  9C5 
binds  to  a  molecule  induced  by  CD40L-transfected  cells 
but not untransfected ~-2  cells.  In addition,  9C5  is a  po- 
tent inhibitor of the clonal expansion of CD4 T  cells when 
CD40L-activated T  cells were used as accessory cells (Fig. 2 
b).  To  test  whether  9C5  also  binds  CD44H,  we  tested 
whether  prototypic  anti-CD44H  mAb  IM1.7  inhibits the 
binding of 9C5  to  CD40L-induced B  cells,  As  shown  in 
Fig.  2  c,  IM1.7  completely  blocks  the  binding  of  9C5~ 
which strongly suggests that 9C5  also binds CD44H,  That 
9C5 binds CD44H  is confirmed by its binding to CD44H- 
transfected,  but not parental,  CHO  cells  (Fig.  2  c).  Thus, 
two  independently derived  mAbs  that  recognize  CD40L- 
induced  costimulatory  activity  bind  CD44H.  Consistent 
with  this,  the  prototype  anti-CD44H  mAb  IM1.7  also 
blocks  CD44H-induced  costimulatory  activity  (data  not 
shown). 
Rapid Induction of CD44H mRNA by CD4OL.  To  test 
whether CD44H  is up-regulated by the CD40L at the level 
of transcription,  we  isolated  total  tLNA  from  B  cells  that 
have  been precultured with  CD40L-transfected  ~-2  cells. 
As shown in Fig.  3,  CD44  mRNA  is rapidly up-regulated 
by  CD40L.  After  normalizing the  RNA  loading,  we  can 
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Figure  4.  CD44H  expressed 
on CHO cells has costimulatory 
activity for the clonal  expansion 
of T  cells. (a)  Levels  of FoR, 
CD44H,  and I.]7 on CHO cells 
transfected  with  FcK  (top), 
FcR+human B7-1  (middh'), and 
FcR+nmrine  CD44H  (bottom). 
The  expression  of FcR,  CD44, 
and B7 was determined  using ei- 
ther lnAbs (2.4G2 for FcR; TM-I 
for  CD44)  or  fusion  protein 
(CTLA41g for B7). (b) Induction 
of clonal  expansion  of CD4  T 
cells.  Given  numbers  of CHO 
cells transfected with either FcR, 
FcP,+B7,  or FcR.+CI)44H were 
used as accessory cells after being 
fixed by 0.15% parafomMdehyde 
for  5  rain.  CD4  T  cells (10s/ 
well) were stinmlated  with  1:40 
dilution  of anti-C1)3  mAb 2C11 
for 42 h, and the proliferation  of 
(;I)4 T  cells was determined  by 
incorporation  of 3H-TdlL in the subsequent 6 h. Solid lines represent the incoporation  of 3H-TdR in cultures containing  both C1)4 T cells and CHO 
cells; whereas dotted lines represent  that of CHO cells alone.  (c) Inhibition  of CD44H-mediated costimulatory  activity by TM-1, as in b, except that 
TM-I was added at a final concentration  ofl.5 b~g/ml. 
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detect about a fivefold increase  of CD44 1KNA within 2 h, 
the earliest  time-point tested,  tt should be noted that upon 
longer exposure,  a significant amount ofCD44  mlKNA are 
detected in resting B  cells (data not shown). 
CD44H Expressed  on CHO Cells Has Costimulatory  Activ- 
ity.for the Ctonal Expansion of T  Cells.  We  have  transfected 
CD44H  cDNA  in  conjunction  with  Fcl:k into  CHO  cells 
to  test  whether  CD44H  has  costimulatory  activity  for  T 
cells.  As  shown  in  Fig.  4,  CHO  cells  cotransfected  with 
CD44H  and  FclL induce  significantly  higher  proliferation 
of CD4  T  cells, as compared to CHO  cells transfected with 
FcR  alone.  These  results  are  reproduced  by  nmltiple  ex- 
periments  using two independently  derived CD44H  trans- 
fectants  (data  not  shown).  Moreover,  anti-CD44H  mAb 
TM-1  significantly  blocks  the  costinmlatory  activi  W  of 
CD44H-transfected  CHO  cells, yet it has  no  effect on  the 
function  of CHO  cells  transfected  with  B7+FcP,..  Thus, 
CD44H  provides sufficient costimulatory activity for clonal 
expansion  of CD4  T  cells.  Interestingly,  we  observed  a 
slight enhancement  of T  cell proliferation  by anti-CD44H 
mAb when CHOFcR  were used as accessory cells. 
To  test  whether  the  costimulatory  activity  of CD44H 
requires  CD28,  we isolated CD4  T  cells from mice with a 
targeted  mutation  of CD28.  Although  CD4  T  cells from 
CD28-deficient  mice  respond  poorly  to  B7,  as  has  been 
described  (32),  they retain  their responsiveness  to  CD44H 
(Fig. 5). 
CHOlwell 
Figure 5.  CD28 (-/-)  CD4 T cells respond to costimulatory activity 
of CD44H but poorly to that  of B7. CD4 T  cells (1.5 ￿  10S/well) iso- 
lated from CD28-deficient mice were stimulated with anti-CD3 inAb in 
the presence of CHO cells transfected with either FcK or FcR plus either 
B7 or CD44H, and the proliferation  of C1)4 T cells was determined  by 
incorporation  of'3H-TdR, as detailed in Fig. 4 legends. Solid lines repre- 
sent the incoporation  of 3H-TdK in cultures containing both CD4 T cells 
and CHO ceils, whereas dotted lines represent that of CHO cells alone. 
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tranffected with either Fcl:L  or FcP,+CD44H,  as detailed in the legend for Fig. 5. Anti-CD44H mAbs  TM-1, 9C5, and 
were added at the beginning of the culture. Mitomycin C-treated CHO cells were added at 3,000 cells/well. Mean 
alone was 2,590. Representatives of two independent experiments. 
Figure 6.  HA is unlikely to be 
the receptor  that transduces the 
costimulatory activity of CD44H. 
(a)  CD40L  does not  induce  B 
cell binding to HA. CHO cells, 
unstimulated B  cells, or B  cells 
cocuhured with ~-2 or CD40L- 
transfected ~-2  cells for  16  h 
were  isolated  and  assayed for 
their  ability to bind FITC-HA. 
Solid  lines  depict  the  fluores- 
cence profiles of cells incubated 
with  FITC-HA, long dash lines 
depict  those  for  autofluores- 
cence, whereas the  dotted  lines 
depict  the  fluorescence of cells 
incubated with unlabeled HA for 
20 rain before addition of FITC- 
HA.  (b)  Human  CD441g does 
not block the  costimulatory ac- 
tivity  of  murine  CD44-trans- 
fected CHO  cells. CD28(-/-) 
CD4  T  cells (1.5  ￿  105/well) 
were stimulated with CHO cells 
IM1.7 and fusion protein HA-Ig 
cpm for CHOFcRCD44H cells 
A  critical question  is the  identity of the  receptor on  T 
cells  that  recognizes  the  CD44H  on  CD40L-induced  B 
cells. To determine whether the best characterized CD44H 
ligand, the HA (29), is involved in costimulation by CD44H, 
we  tested  if CD40L  enhances  B  cell binding  to  HA.  As 
shown  in  Fig.  6  a,  much  like  resting  B  cells,  CD40L- 
induced B  cells do not bind to HA. CHO  cells that express 
hamster  CD44H  bind  HA  significantly.  Thus,  CD40L- 
induced CD44H  does not bind HA. These results strongly 
suggest that HA is not the receptor on T  cells that receive 
the  costimulatory activity of CD40L-induced  CD44.  To 
formally rule out the involvement of HA, we used human 
CD44Ig,  which  is  known  to  react  with  mouse  HA,  to 
block T  cell proliferation when CHO  cells transfected with 
mouse  CD44H  were  used as accessory cells. As shown  in 
Fig. 6  b, three anti-CD44H mAbs, but not CD44Ig, block 
T  cell proliferation. These results strongly suggest that HA- 
binding is unlikely to be responsible for the  costimulatory 
activity of CD44H. 
Discussion 
CD40L  induces  costimulatory  activity  on  B  cells  and 
perhaps  other CD40 +  cells such  as dendritic cells, macro- 
phages, and epithelial cells (1,  19-21). Although it is known 
that CD40L can induce B7 family member B7-1 and B7-2, 
such induction does not fully explain CD40L-induced co- 
stimulatory activity on B  cells because the induction of co- 
stimulatory activity precedes that of B7-2 (19). This dispar- 
ity in kinetics of induction reveals that the CD40L-induced 
costimulatory  activity  is  at  least  partly  distinct  from  B7 
family members. To study the molecular basis of CD40L- 
induced costimulatory activity, we have recently produced 
an mAb, TM-1, that blocks such costimulatory activity (19). 
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We showed by expression cloning that TM-1  and 9C5, an- 
other  independently  derived  mAb  of similar  properties, 
binds  CD44H.  In  addition,  we  showed  that  CD44H  ex- 
pressed on CHO  cells has costimulatory activity for clonal 
expansion of CD4  T  cells. These  results demonstrate  that 
CD44H  is  a  costimulatory  molecule  rapidly  induced  by 
CD40L.  CD44H  is  expressed  at  a  low  level in  resting T 
and B  cells (33, 34). It is upregulated and posttranslationally 
modified after lymphocyte activation (34).  However, such 
rapid induction  of CD44H  by  CD40L,  as  reported here, 
has  not  been  documented.  Several  previous  studies  have 
implicated a role of CD44H  (on T  cells) in T  cell costimu- 
lation, perhaps as a receptor for costirnulatory molecules on 
APC (35, 36). These studies may explain the augmentation 
of T  cell  proliferation  by  anti-CD44H  mAb  when  the 
FcP,-transfected CHO  cells were used as APCs. Neverthe- 
less, our study appears to be the first to directly demonstrate 
a role of CD44H as a costimulatory molecule on the APCs, 
and  the  first  direct  demonstration  that  recombinant 
CD44H  is sufficient to costimulate proliferation of T  cells 
by a CD28-independent mechanism. 
Corresponding to the heterogeneity of the CD44 mole- 
cules,  a  large array of CD44  ligands have  been  described. 
The  best  characterized ligand for  CD44  is HA  (29).  This 
binding requires  at least two  basic  amino  acids spaced by 
seven amino acids (37).  It also requires clustering of CD44 
molecules since mutations affecting this process have been 
reported to interfere with this interaction (31, 38, 39). The 
CD44H  form  (containing no  variable exon)  is  known  to 
bind HA (31). On lymphocytes, such binding can be regu- 
lated by cellular activation events (40). Several other mole- 
cules, such as fibronectin (41), collagen (42), serglycin (43), 
the chondrotin sulfate form of invariant chain encoded by 
MHC  region  (44),  as well as CD44P,1  (v8-10  containing CD44)  (45),  have  also been  reported to  bind CD44.  The 
receptor on T  cells that interacts with the CD40L-induced 
CD44H to transduce the costimulatory signal remains to be 
identified. As HA-binding of CD44H is known to be regu- 
lated by cellular activation (40), it is of great interest to de- 
termine  whether  HA  is such  a  receptor.  Our results  pre- 
sented  here  demonstrate  that  CD40L-induced  B  cells do 
not bind HA and that human CD44Ig that binds HA does 
not  block  T  cell  proliferation  when  CD44H-transfected 
CHO  cells were used as accessory cells. Thus, it is very un- 
likley that HA is the receptor responsible for the costimula- 
tory activity of CD44H  expressed on APCs.  These results 
may also explain poor costimulatory activity of CHO  cells 
despite of their strong binding to HA. 
Recent studies demonstrate that CD40L is involved in T 
cell priming  in  vivo  (9,  10).  Several  different  hypotheses 
can  be  proposed  to  explain  the  role  of  CD40L.  First, 
CD40L may be delivering costimulatory signal to T  cells, as 
has  been  suggested by Cayabyab et al.  (46).  However,  in 
our  experience,  T  cells  from  CD40L-deficient  mice  re- 
spond to costimulatory activity on the previously activated 
B  ceils (47). Thus,  CD40L is unlikely to be necessary for T 
cells to receive costimulatory activity from APCs.  Second, 
CD40L may be involved in inducing costimulatory activity 
on  the APCs.  The  second hypothesis is attractive because 
results  from  numerous  experiments  show  that  CD40L/ 
CD40  interaction  is  both  necessary and  sufficient for  in- 
ducing costimulatory activity on B  cells (1,  19-21).  In ad- 
dition,  blocking  CD40L/CD40  interaction  facilitates  in- 
duction  of tolerance  by  B  cells  (18),  consistent  with  the 
idea that T  cell costimulation was blocked by this treatment 
(13-17).  Our current study shows that CD44H is one such 
costimulatory molecule that fulfills all known properties of 
the  costimulatory molecules induced  by  CD40L,  namely, 
rapid induction, and CD28-independence in function. Our 
study should also facilitate the effort to determine the mo- 
lecular basis of CD40L function in T  cell responses. 
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